39.50 0.00 (0.00%)
After hours: 5:02PM EDT
|Bid||38.06 x 200|
|Ask||39.60 x 500|
|Day's Range||38.56 - 39.63|
|52 Week Range||29.39 - 47.82|
|PE Ratio (TTM)||30.38|
|Earnings Date||May 8, 2018 - May 14, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||49.86|
Wall Street analysts estimate Bristol-Myers Squibb’s top line to rise 6.5% to ~$5.2 billion in 1Q18. Also, the earnings per share are expected at $0.85 for 1Q18. The revenue growth is expected to be driven by the prioritized brands including Opdivo, Empliciti, Eliquis, Orencia, Sprycel, and Yervoy, partially offset by lower sales of established brands.
Johnson & Johnson’s (JNJ) medical devices business includes cardiovascular care products, orthopedics products, surgery products, vision care products, and diabetes products. The medical devices business reported 7.5% growth in revenues to $6.8 billion during 1Q18 as compared to revenues of $6.3 billion during 1Q17. The growth includes 3.2% growth in revenues at constant exchange rates and a 4.3% increase due to the positive impact of foreign exchange.
HERTFORDSHIRE, England and PITTSBURGH, April 25, 2018 /PRNewswire/ -- Global pharmaceutical company Mylan N.V. (MYL) today announced the U.S. launch of Drospirenone and Ethinyl Estradiol Tablets USP, 3 mg/0.02 mg, a generic version of Bayer's Yaz® Tablets. Mylan Pharmaceuticals received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for this product, which is indicated for use by women to prevent pregnancy and for the treatment of acne vulgaris in women at least 14 years of age who have achieved menarche and desire an oral contraceptive for birth control. In the U.S., Mylan offers more than 20 generic birth control medicines in multiple dosage forms.
U.S. prosecutors were nearing their first charges against generic-drug companies in a nearly four-year-old criminal probe into a possible price-fixing, Bloomberg reported, citing people familiar with the matter. Soaring drug prices from both branded and generic drugmakers have sparked outrage and investigations in the past, with President Donald Trump last year calling it "getting away with murder". In October, Reuters reported https://www.reuters.com/article/us-usa-generics/u-s-states-allege-broad-generic-drug-price-fixing-collusion-idUSKBN1D0201 a lawsuit on the price-fixing case accused 18 companies, including Mylan and Teva Pharmaceutical, and named 15 medicines.
U.S. prosecutors are nearing their first charges against companies in an almost four-year-old criminal investigation into alleged price-fixing by generic-drug makers, according to people familiar with ...
In spite of reports that Wegmans pharmacies are out of stock of the EpiPen allergic reaction treatment, the Food and Drug Administration is not currently aware of any U.S. shortage, though the regulator continues to monitor the supply, spokesperson Lauren Smith Dyer. Pfizer , which manufactures the Mylan product through one of its business units, said that it is currently shipping products but supplies may vary from pharmacy to pharmacy.
Three posters highlight Mylan's rigorous Glatiramer Acetate development program HERTFORDSHIRE, England , and PITTSBURGH , April 21, 2018 /PRNewswire/ -- Global pharmaceutical company Mylan N.V. (NASDAQ: ...
Generic drugmaker Mylan NV on Friday announced layoffs of about 15 percent of its workforce at a pharmaceutical manufacturing plant in Morgantown, West Virginia. The company, which had faced intense criticism and political scrutiny over price hikes for its life-saving EpiPen emergency allergy treatment, said the Morgantown plant "needed to be rightsized to be less complex" for continued operations. The layoffs involved more than 400 employees represented by a United Steel Workers local union, reported WAJR, a Morgantown radio station.
Canada said on Tuesday it is working with the U.S. Food and Drug Administration to access supplies of Mylan N.V.'s EpiPen emergency allergy antidote amid a growing shortage that has spared the United States. EpiPens deliver a potentially lifesaving dose of the generic drug epinephrine via an automatic injector. Last week, Pfizer notified consumers in Canada and Britain that the device is in short supply due to manufacturing problems.
At first glance, Pfizer Inc. (NYSE:PFE) appears a worthwhile contrarian trade. Additionally, the overall markets have been soft, allowing shrewd investors to pick up PFE stock at a more attractive valuation. As a result, many analysts are questioning whether Pfizer stock, at its present cost, is worth the risk.
Yahoo Finance's Jared Blikre joins Seana Smith from the floor of the New York Stock Exchange to discuss the latest market moves.
Yahoo Finance's Jared Blikre and Alexis Christoforous break down the latest market action.